Clinical Trial Update: The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates RAD 001 (everolimus) as second-line therapy for urothelial cancer (transitional cell carcinoma of the urothelium); the study has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transitional Cell Carcinoma of the Urothelium
• Urothelial Cancer

Drugs mentioned

• RAD 001 (ridaforolimus)

Snippet

Sponsor: Hopital Foch | Conditions: Urothelial Cancer | Phase 2 | Status: COMPLETED